Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Read more

First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Read more

Medivir to present at the Stockholm Corporate Finance Life Science Day

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.